Atrial FibrillationNCT00293943
Randomized Trial of Two Different Strategies to Treat Paroxysmal Atrial Fibrillation
A study testing Pulmonary vein ablation in people with Atrial Fibrillation, run by Atrial Fibrillation Network at 3 sites in Germany.
Trial summary
The purpose of this study is to investigate the significance of complete versus incomplete electrical isolation of pulmonary veins by radiofrequency-induced linear lesions in patients with paroxysmal atrial fibrillation. Read more about this study
- Who is it for?
- Ages 50 to 85 years
- Conditions the study is for
- Atrial Fibrillation
- What is being tested?
- Pulmonary vein ablation
- Type of treatment
- Surgery or procedure
- How many people
- 232 participants
- Where
- 3 sitesGermany
- Study dates
- Feb 2006to Aug 2010
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Idiopathic paroxysmal symptomatic atrial fibrillation refractory to antiarrhythmic therapy
- Age 50 - 85 years
- Patient willing to participate in randomized trial and an invasive follow-up at month 3 (-6)
- Structural normal heart
- Patient willing and able to participate in 12 months follow-up period
- ECG documentation of atrial fibrillation (ECG, Holter, event recorders, etc) for at least one AF event in the prior year (related to symptomatic or asymptomatic episodes) with an average number of one episode per month
- Written informed consent of the patient
Who cannot join
- Patients who have had previous pulmonary vein ablation procedures Patients with atrial fibrillation secondary to a reversible cause
- Known presence of intracardiac or other thrombi
- Evidence of obstructive lung disease requiring bronchodilator therapy
- Pregnant females or those of child bearing potential who have not had a negative pregnancy test within 48 hours before treatment.
- Other medical illness (i.e. cancer, congestive heart failure) that may cause the patient to be non-compliant with the protocol, confound the data interpretation or is associated with limited life-expectancy (i.e., less than one year)
- History of bleeding diathesis or suspected pro-coagulant state contraindication to anticoagulation therapy
Show all 11Show fewer
- Hyperthyroidism or hypothyroidism manifested clinically and in laboratory tests (TSH, T3, T4)
- Participation in a clinical trial within the last 30 days. Simultaneous participation in a registry (e.g. project AB1 of the AFNET) is permitted.
- Drug addiction or chronic alcohol abuse
- Legal incapacity, or other circumstances which would prevent the patient from understanding the aim, nature or extent of the clinical trial
- Evidence of an uncooperative attitude
Trial locations and contacts
3 sites in 1 country.
Germany3 sites
General Hospital St. Georg, Department of Cardiology
Hamburg, 20099
University Cardiac Center
Hamburg, 20246
University Hospital, Department of Cardiology
Münster, 48149
About this study
Official title: A Randomized Trial to Investigate the Significance of Complete Versus Incomplete Electrical Isolation of Pulmonary Veins by Radiofrequency-induced Linear Lesions
The purpose of this study is to investigate the significance of complete versus incomplete electrical isolation of pulmonary veins by radiofrequency-induced linear lesions in patients with paroxysmal atrial fibrillation.
The study hypothesis ist that the complete linear PV isolation ablation is superior to the non-complete linear PV isolation on the outcome of patients with idiopathic drug-refractory atrial fibrillation. As a second hypothesis in this adaptive study design, the non-inferiority of the complete linear PV isolation strategy will be tested.
Read the detailed description
Atrial fibrillation can be cured by elimination of triggering events such as atrial extrasystoles originating from the pulmonary veins (PV) by selective or linear radiofrequency current applications.
Although electrical isolation can be demonstrated by a circumferential mapping catheter positioned at the PV ostium, longterm effect of such EP-guided PV isolation procedures achieve about 60-70% of stable sinus rhythm during follow-up even in experienced centers. Re-investigation of symptomatic patients after initially electrically isolated PVs demonstrated a substantial amount of PV reconduction which might explain the arrhythmia recurrence.
Although it was demonstrated that linear lesions for PV isolation is superior to the selective ablation approach, conflicting data exists on the necessity to achieve complete linear lesions. The groups of Pappone et al and Oral et al both published a success rate of more than 90% of patients in sinusrhythm irrespective of the line completeness, which both groups estimated to be reached in only 30% of cases.
Several advantages and disadvantages could advocate for either the complete versus the incomplete ablation strategy: Performing the complete EP-guided linear PV isolation strategy might take longer (mean duration 4.5 hours vs about 2 hours) and could thereby potentially result in a higher risk of procedure-associated complications (air embolism, thrombus formation, perforation). In addition, three transseptal sheaths might increase the risk of tamponade and might aggravate the ability to safely navigate catheters in the left atrium. Certainly, the procedure costs are higher, since in addition to the 3D mapping system two circular mapping catheters are mandatory to facilitate the lesion deployment and avoidance of intra-PV ablation.
In addition, an ablation strategy that does not depend on complete line deployment may be sufficient to achieve stable sinus rhythm. Although, additional linear lesions between the PV isolation segments and towards the mitral annulus as proposed by several centers with incomplete linear PV isolation approaches might not be necessary to achieve stable sinus rhythm. Potential complications such as atrio-esophageal fistula formation could be avoided if no additional lesions eg. along the LA roof would be necessary. Both the costs of the additional material (transseptal sheaths, circular mapping catheters) and the shorter procedure duration (about 2 hours) would be reduced. On the other hand, these costs would be balanced by the reduced number of re-ablation, if incomplete PV isolation would indeed lead to a higher AF recurrence rate.
Since no data exist on the time course of the deployed ablation lines. Do patients with recurrences of AF always have PV reconduction ? Vice versa, it also remains unclear if all patients with stable sinus rhythm do experience this effect based on longterm PV isolation. To assess the significance of the time course of PV isolation, the proposed study protocol consists therefore of an invasive re-evaluation of all primarily ablated pts scheduled after 3 months of follow-up regardless of arrhythmia recurrence to investigate PV conduction properties.
Finally, patients with symptomatic AF who underwent intensified ECG monitoring indicate that the standard clinical procedures (assessment of symptoms and surface ECG recordings at long intervals) are not sufficient to detect recurrent AF. Therefore, daily ECG monitoring is planned in this trial to detect asymptomatic episodes of AF.
The proposed study protocol aims to investigate in prospective, randomized fashion the significance of complete versus incomplete PV isolation by RFC-induced linear lesions. The ablation will be randomized to a linear encircling around the ipsilateral PVs with the endpoint of complete PV isolation proven by two circumferential mapping catheters versus the same ablation procedure which will be terminated instantaneously when total PV isolation occurs, thereby allowing at least one conduction gap along the isolation line. An invasive re-evaluation is scheduled after 3 months for all pts to assess longterm PV conduction properties.
- Conditions
- Atrial Fibrillation
- Being tested
- Pulmonary vein ablation
- Keywords
- Atrial fibrillation, Pulmonary vein ablation, Linear lesions
- Medical subject headings
- Atrial Fibrillation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pulmonary vein ablationProcedure or surgery
What is being measured
The primary outcome is the main question the study is designed to answer.
- Time to first recurrence of symptomatic AF with duration of more than 30 sec on trans-telephonic ECG monitoring or detection of asymptomatic AF defined as 2 consecutive recordings of AF during a minimum of 72 hours
Time to first recurrence of symptomatic AF with duration of more than 30 sec on trans-telephonic ECG monitoring or detection of asymptomatic AF defined as 2 consecutive recordings of AF during a minimum of 72 hours
Secondary outcomes (8)
- Time to first occurrence of any documented relapse of atrial fibrillation
- Time to first occurrence of any documented relapse of atrial fibrillation
- Number and total duration of documented AF episodes
- Number and total duration of documented AF episodes
- Number of hospitalizations due to atrial fibrillation
- Number of hospitalizations due to atrial fibrillation
- Number of visits without hospitalization
- Number of visits without hospitalization
- Number of "serious adverse events of special interest"
- Number of "serious adverse events of special interest"
- Procedure parameters (duration, fluoroscopy, number of radiofrequency applications)
- Procedure parameters (duration, fluoroscopy, number of radiofrequency applications)
- Procedural costs (including the costs of re-ablation if AF recurrence occurs)
- Procedural costs (including the costs of re-ablation if AF recurrence occurs)
- Quality of life
- Quality of life
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Feb 2006 (estimated)
- Study startFeb 2006
- Primary completionMar 2010
- Study completionAug 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Atrial FibrillationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 232 participants (actual)
Sponsor and investigators
- Lead sponsor
- Atrial Fibrillation Network
- Sponsor type
- University, hospital or other
- Collaborators
- C. R. Bard, Biosense Webster, Inc., Abbott Medical Devices, Medtronic
- Responsible party
- Sponsor
- Investigators
- Günter Breithardt, MD, Principal investigator, Universität MünsterKarl-Heinz Kuck, MD, Principal investigator, General Hospital St. Georg, HamburgStephan Willems, MD, Principal investigator, Universitätsklinikum Hamburg-Eppendorf
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00293943
- Sponsor's protocol ID
- AFNET-B04-1
- Status last verified
- Sep 2012
- First submitted
- 17 Feb 2006
- Last updated
- 10 Sep 2012
- Results posted
- No
Publications
Kuck KH, Hoffmann BA, Ernst S, Wegscheider K, Treszl A, Metzner A, Eckardt L, Lewalter T, Breithardt G, Willems S; Gap-AF-AFNET 1 Investigators*. Impact of Complete Versus Incomplete Circumferential Lines Around the Pulmonary Veins During Catheter Ablation of Paroxysmal Atrial Fibrillation: Results From the Gap-Atrial Fibrillation-German Atrial Fibrillation Competence Network 1 Trial. Circ Arrhythm Electrophysiol. 2016 Jan;9(1):e003337. doi: 10.1161/CIRCEP.115.003337.
PubMed 26763226
Study at a glance
From the registry record, last updated by the sponsor on 10 Sep 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Trial to Investigate the Significance of Complete Versus Incomplete Electrical Isolation of Pulmonary Veins by Radiofrequency-induced Linear Lesions
- ClinicalTrials.gov ID
- NCT00293943
- Acronym / sponsor ID
- AFNET-B04-1
- Conditions
- Atrial Fibrillation
- Keywords
- Atrial fibrillation, Pulmonary vein ablation, Linear lesions
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 232 participants (actual)
- Lead sponsor
- Atrial Fibrillation NetworkUniversity, hospital or other
- Collaborators
- C. R. Bard, Biosense Webster, Inc., Abbott Medical Devices, Medtronic
- Study start
- Feb 2006
- Primary completion
- Mar 2010 (actual)
- Study completion
- Aug 2010 (actual)
- First posted
- 20 Feb 2006 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to investigate the significance of complete versus incomplete electrical isolation of pulmonary veins by radiofrequency-induced linear lesions in patients with paroxysmal atrial fibrillation.
The study hypothesis ist that the complete linear PV isolation ablation is superior to the non-complete linear PV isolation on the outcome of patients with idiopathic drug-refractory atrial fibrillation. As a second hypothesis in this adaptive study design, the non-inferiority of the complete linear PV isolation strategy will be tested.
Detailed description
Atrial fibrillation can be cured by elimination of triggering events such as atrial extrasystoles originating from the pulmonary veins (PV) by selective or linear radiofrequency current applications.
Although electrical isolation can be demonstrated by a circumferential mapping catheter positioned at the PV ostium, longterm effect of such EP-guided PV isolation procedures achieve about 60-70% of stable sinus rhythm during follow-up even in experienced centers. Re-investigation of symptomatic patients after initially electrically isolated PVs demonstrated a substantial amount of PV reconduction which might explain the arrhythmia recurrence.
Although it was demonstrated that linear lesions for PV isolation is superior to the selective ablation approach, conflicting data exists on the necessity to achieve complete linear lesions. The groups of Pappone et al and Oral et al both published a success rate of more than 90% of patients in sinusrhythm irrespective of the line completeness, which both groups estimated to be reached in only 30% of cases.
Several advantages and disadvantages could advocate for either the complete versus the incomplete ablation strategy: Performing the complete EP-guided linear PV isolation strategy might take longer (mean duration 4.5 hours vs about 2 hours) and could thereby potentially result in a higher risk of procedure-associated complications (air embolism, thrombus formation, perforation). In addition, three transseptal sheaths might increase the risk of tamponade and might aggravate the ability to safely navigate catheters in the left atrium. Certainly, the procedure costs are higher, since in addition to the 3D mapping system two circular mapping catheters are mandatory to facilitate the lesion deployment and avoidance of intra-PV ablation.
In addition, an ablation strategy that does not depend on complete line deployment may be sufficient to achieve stable sinus rhythm. Although, additional linear lesions between the PV isolation segments and towards the mitral annulus as proposed by several centers with incomplete linear PV isolation approaches might not be necessary to achieve stable sinus rhythm. Potential complications such as atrio-esophageal fistula formation could be avoided if no additional lesions eg. along the LA roof would be necessary. Both the costs of the additional material (transseptal sheaths, circular mapping catheters) and the shorter procedure duration (about 2 hours) would be reduced. On the other hand, these costs would be balanced by the reduced number of re-ablation, if incomplete PV isolation would indeed lead to a higher AF recurrence rate.
Since no data exist on the time course of the deployed ablation lines. Do patients with recurrences of AF always have PV reconduction ? Vice versa, it also remains unclear if all patients with stable sinus rhythm do experience this effect based on longterm PV isolation. To assess the significance of the time course of PV isolation, the proposed study protocol consists therefore of an invasive re-evaluation of all primarily ablated pts scheduled after 3 months of follow-up regardless of arrhythmia recurrence to investigate PV conduction properties.
Finally, patients with symptomatic AF who underwent intensified ECG monitoring indicate that the standard clinical procedures (assessment of symptoms and surface ECG recordings at long intervals) are not sufficient to detect recurrent AF. Therefore, daily ECG monitoring is planned in this trial to detect asymptomatic episodes of AF.
The proposed study protocol aims to investigate in prospective, randomized fashion the significance of complete versus incomplete PV isolation by RFC-induced linear lesions. The ablation will be randomized to a linear encircling around the ipsilateral PVs with the endpoint of complete PV isolation proven by two circumferential mapping catheters versus the same ablation procedure which will be terminated instantaneously when total PV isolation occurs, thereby allowing at least one conduction gap along the isolation line. An invasive re-evaluation is scheduled after 3 months for all pts to assess longterm PV conduction properties.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
Who may qualify
- Ages
- 50 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Idiopathic paroxysmal symptomatic atrial fibrillation refractory to antiarrhythmic therapy
- Age 50 - 85 years
- Patient willing to participate in randomized trial and an invasive follow-up at month 3 (-6)
- Structural normal heart
- Patient willing and able to participate in 12 months follow-up period
Key exclusion criteria (11 listed)
- Patients who have had previous pulmonary vein ablation procedures Patients with atrial fibrillation secondary to a reversible cause
- Known presence of intracardiac or other thrombi
- Evidence of obstructive lung disease requiring bronchodilator therapy
- Pregnant females or those of child bearing potential who have not had a negative pregnancy test within 48 hours before treatment.
- Other medical illness (i.e. cancer, congestive heart failure) that may cause the patient to be non-compliant with the protocol, confound the data interpretation or is associated with limited life-expectancy (i.e., less than one year)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pulmonary vein ablation | Procedure or surgery | – |
Primary outcome
- Time to first recurrence of symptomatic AF with duration of more than 30 sec on trans-telephonic ECG monitoring or detection of asymptomatic AF defined as 2 consecutive recordings of AF during a minimum of 72 hours
Time to first recurrence of symptomatic AF with duration of more than 30 sec on trans-telephonic ECG monitoring or detection of asymptomatic AF defined as 2 consecutive recordings of AF during a minimum of 72 hours
8 secondary outcomes
- Time to first occurrence of any documented relapse of atrial fibrillation
- Number and total duration of documented AF episodes
- Number of hospitalizations due to atrial fibrillation
- Number of visits without hospitalization
- Number of "serious adverse events of special interest"
- Procedure parameters (duration, fluoroscopy, number of radiofrequency applications)
- Procedural costs (including the costs of re-ablation if AF recurrence occurs)
- Quality of life
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Sep 2012.
- Derived from this study: PubMed 26763226Kuck KH, Hoffmann BA, Ernst S, Wegscheider K, Treszl A, Metzner A, Eckardt L, Lewalter T, Breithardt G, Willems S; Gap-AF-AFNET 1 Investigators*. Impact of Complete Versus Incomplete Circumferential Lines Around the Pulmonary Veins During Catheter Ablation of Paroxysmal Atrial Fibrillation: Results From the Gap-Atrial Fibrillation-German Atrial Fibrillation Competence Network 1 Trial. Circ Arrhythm Electrophysiol. 2016 Jan;9(1):e003337. doi: 10.1161/CIRCEP.115.003337.
- Homepage of the German Atrial Fibrillation NetworkLink provided by the sponsor.
Related trials for Atrial Fibrillation
Active, not recruiting
Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)
Paroxysmal AF
Active, not recruitingObservational study
Concomitant Left Atrial Appendage Closure and Pulsed Field Ablation-Asia
Concomitant Procedures, Atrial Fibrillation
Active, not recruiting
CONVERGE Post-Approval Study (PAS)
Chronic Atrial Fibrillation
Recruiting
Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy
Ischemic Stroke, Atrial Fibrillation
RecruitingPhase 2
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Atrial Fibrillation (AF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Günter Breithardt, MD principal investigator
Universität Münster
Karl-Heinz Kuck, MD principal investigator
General Hospital St. Georg, Hamburg
Stephan Willems, MD principal investigator
Universitätsklinikum Hamburg-Eppendorf
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Pulmonary vein ablation in people with Atrial Fibrillation, run by Atrial Fibrillation Network at 3 sites in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Sep 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
- Time to first recurrence of symptomatic AF with duration of more than 30 sec on trans-telephonic ECG monitoring or detection of asymptomatic AF defined as 2 consecutive recordings of AF during a minimum of 72 hours. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00293943, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Sep 2012; AzTrials last refreshed its copy on 8 Nov 2026.